Missouri Judge Approves $7.25 Billion Roundup Settlement: Bayer to Pay Over Two Decades
The agreement resolves thousands of cancer claims and establishes average payouts between $10,000 and $165,000 for current and future plaintiffs.
By Amit Chukwu ·

Bayer will pay a maximum of $7.25 billion over the next 20 years to settle thousands of lawsuits from U.S. cancer patients. A Missouri judge approved the agreement on Friday. The payments cover claims that the company failed to warn users that its weedkiller Roundup could cause non-Hodgkin lymphoma.
The settlement covers two groups of people. It includes those who are already ill and those who receive a diagnosis of non-Hodgkin lymphoma in the future. Individual payouts are expected to average between $10,000 and $165,000. The final amount depends on the user's age at diagnosis, the severity of their illness, and how they used the product.
Bayer, a Germany-based agrochemical maker, denies that Roundup causes cancer. The company faces mounting litigation costs that have led it to consider removing the product from U.S. agricultural markets. The settlement provides financial certainty against these rising legal expenses.
The legal landscape shifted while the settlement was pending. In June, the U.S. Supreme Court ruled that Bayer cannot be sued in state courts for failing to warn about cancer. The high court determined that federal regulations do not require a cancer warning label. It also ruled that states are forbidden from imposing additional labeling requirements on the product.
Attorneys for cancer patients have mixed views on the deal. Some contend the payouts are too small. Others argue the agreement is better than receiving nothing, a risk that increased after the Supreme Court ruling. St. Louis Circuit Judge Timothy Boyer approved the plan in a written judgment. He described the average individual payouts as fair and adequate. He noted that the total dollar amount is among the largest in the history of mass tort personal-injury class action settlements.
Bill Anderson, CEO of Bayer, called the court-approved settlement a decisive milestone. He stated that it helps mitigate the risks of both pending and future Roundup litigation. The decision remains subject to appeal. Bayer acquired Monsanto in 2018, which brought the Roundup brand and its associated lawsuits into its portfolio.
Monsanto, based in Missouri, introduced Roundup in 1974 with glyphosate as its active ingredient. The product became one of the most widely used herbicides in agriculture. It is designed for use with genetically modified seeds that resist the chemical. Farmers use it to produce more while tilling soil less. The product is also common on residential lawns and gardens.
About 200,000 claims have been made against Bayer, many from residential users. The company has removed glyphosate from new versions of Roundup sold for residential markets. Scientific agencies disagree on the chemical's risks. The World Health Organization classified glyphosate as probably carcinogenic in 2015. The U.S. Environmental Protection Agency determined it is not likely to cause cancer in humans when used as directed. In October, a Missouri jury sided with Bayer in the first verdict since the Supreme Court ruling. The jury rejected claims of design defects, negligence, and fraud.
More Business · Customer Complaints · Report a business · Got a Story?






